2. Immunology/Inflammation
  3. CD19

CD19

CD19 is a 95 kD transmembrane glycoprotein that is highly expressed in human B cells and certain types of tumors, belonging to the immunoglobulin superfamily. CD19 plays a crucial role in regulating the threshold of B cell signaling by modulating both B cell receptor (BCR)-dependent and independent signaling pathways, thereby playing an essential role in the initiation of immune responses and the maintenance of tolerance. CD19 typically forms a multimolecular complex with molecules like CD21 and CD81 on the surface of mature B cells, where it exerts its dominant signaling function.
CD19 works in cooperation with the BCR to promote the activation of Src family protein tyrosine kinases, enhancing B cell proliferation and expansion. It can also independently enhance B cell activation by binding to the complement receptor CD21. Mice and humans lacking CD19 show weakened T cell-dependent immune responses and low levels of immunoglobulins, leading to immune dysfunction. High expression of CD19 is closely associated with B cell lymphoma, acute lymphoblastic leukemia (ALL), and other malignancies. CD19 monoclonal antibodies are used in the study of B cell malignancies[1].

CD19 Related Products (24):

Cat. No. Product Name Effect Purity
  • HY-P99113
    Inebilizumab Inhibitor
    Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research[1].
  • HY-P9963
    Blinatumomab Inhibitor 98.78%
    Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia[1][2][3][4].
  • HY-P99761
    Obexelimab Inhibitor
    Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus[1][2][3].
  • HY-P99711
    Loncastuximab Inhibitor
    Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349)[1][2].
  • HY-P99868
    Duvortuxizumab
    Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E[1].
  • HY-P991176
    RG-6333 Agonist
    RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003)[1][2].
  • HY-P991231
    DI-B4 Inhibitor
    DI-B4 is an anti-CD19 monoclonal antibody that can bind to CD19 on the surface of B cells and has anti-tumor activity[1].
  • HY-153084
    CD19 CAR mRNA (Mouse)
    CD19 CAR mRNA (Mouse) expresses mouse CD19 CAR protein. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia[1][2][3].
  • HY-153233
    CD19 car mRNA (Mouse)-LNP
    CD19 car mRNA (Mouse)-LNP is a lipid nanoparticle (LNP) containing CD19 car mRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car mRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction[1][2].
  • HY-P99914
    Emfizatamab
    Emfizatamab is an anti-CD19/CD3E/TNFRSF9/PD-L1 monoclonal antibody[1].
  • HY-P990729
    Budoprutug
    Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody[1]. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P990349
    Anti-CD19 Antibody Inhibitor
    The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P990017
    Englumafusp alfa Inhibitor 99.93%
    Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells[1].
  • HY-153085
    CD19 CAR circRNA
    CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
  • HY-P99577
    Taplitumomab
    Taplitumomab is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.
  • HY-P99113A
    Inebilizumab (FUT8-KO)
    Inebilizumab (FUT8-KO) is an anti-CD19 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.Inebilizumab (FUT8-KO) exhibits enhanced ADCC against B cells and can be used for research on multiple sclerosis and neuromyelitis optica[1][2].
  • HY-P990870
    Anti-CD19 Antibody (4G7)
    Anti-CD19 Antibody (4G7) is a kind of mouse IgG1 chimeric antibody, targeting to human CD19. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
  • HY-P990571
    Coltuximab Inhibitor
    Coltuximab is a CHO-expressed humanized antibody that targets CD19. Coltuximab is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Coltuximab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P99285
    Denintuzumab Inhibitor
    Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia[1].
  • HY-P990694
    Zeripatamig
    Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody[1]. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).